Loading...
Loading...
Innate Pharma SA
Innate Pharma SA. Spoken Alpha tracks IPHYF's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks IPHYF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for IPHYF.
curl https://api.spokenalpha.com/v1/companies/IPHYF| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.39 | $1.78 | -21.7% | -1.1% | -1.6% |
| Q4 FY2026 | $1.48 | $1.73 | -14.7% | -6.9% | -4.4% |
| Q3 FY2026 | $1.39 | $1.79 | -22.4% | -1.2% | -1.1% |
| Q2 FY2026 | $1.53 | $1.94 | -21.2% | -5.5% | -6.9% |
| Q1 FY2025 | $1.69 | $2.05 | -17.7% | -5.7% | -7.4% |
| Q4 FY2025 | $1.41 | $1.84 | -23.4% | -6.9% | -7.6% |
| Q3 FY2025 | $1.66 | $1.82 | -8.8% | -7.8% | -6.2% |
| Q2 FY2025 | $1.67 | $2.07 | -19.2% | +0.6% | -0.7% |
| Q1 FY2024 | $1.53 | $2.00 | -23.5% | -6.4% | -5.3% |
| Q4 FY2024 | $1.77 | $2.08 | -15.0% | +1.5% | +0.6% |